Lexicon Pharmaceuticals Stock Fair Value – LEXICON PHARMACEUTICALS Reports Third Quarter FY2023 Earnings Results on November 8, 2023
November 20, 2023
🌥️Earnings Overview
On November 8, 2023, LEXICON PHARMACEUTICALS ($NASDAQ:LXRX) reported their third quarter earnings results for FY2023 (September 30, 2023). Total revenue decreased from the previous year’s USD 0.0 million to USD 0.2 million this year. Net income decreased significantly from -23.4 million last year to -50.5 million this year.
Price History
On the news, the stock opened at $1.1 and closed at the same price, resulting in an 8.8% drop from the previous closing price of $1.2. This drop in stock price was largely attributed to the company’s overall performance in the third quarter of FY2023, which fell short of investors’ expectations. Despite the initial slump in stock price, investors were optimistic about the company’s future prospects as LEXICON PHARMACEUTICALS released a statement regarding their future plans and strategies for the remainder of FY2023. These plans included increasing their research and development activities and launching more innovative products that could help them regain their market share and improve their financials in the coming quarters. The company also highlighted its commitment to creating value for its stakeholders, with plans to introduce new technologies and expand into new markets.
With their plans for the future in place, LEXICON PHARMACEUTICALS has positioned itself to become a leader in the pharmaceuticals industry and take advantage of the growth opportunities available in the market. Overall, investors were satisfied with LEXICON PHARMACEUTICALS’ third quarter FY2023 earnings results, despite the initial decline in stock price. The company’s future plans have given investors confidence that it will deliver strong financial performance in the coming quarters, and that their stock prices will continue to rise over time. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Lexicon Pharmaceuticals. More…
| Total Revenues | Net Income | Net Margin |
| 0.53 | -157.86 | -29784.3% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Lexicon Pharmaceuticals. More…
| Operations | Investing | Financing |
| -132.92 | -77.67 | 212.87 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Lexicon Pharmaceuticals. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 276.48 | 136.97 | 0.57 |
Key Ratios Snapshot
Some of the financial key ratios for Lexicon Pharmaceuticals are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| -74.6% | – | -28127.2% |
| FCF Margin | ROE | ROA |
| -25402.6% | -57.2% | -33.7% |
Analysis – Lexicon Pharmaceuticals Stock Fair Value
At GoodWhale, we provide comprehensive fundamental analysis of LEXICON PHARMACEUTICALS for investors. Our proprietary Valuation Line tool enables us to calculate the intrinsic value of the stock and compare it with the current market price. According to our calculations, the intrinsic value of a share of LEXICON PHARMACEUTICALS is around $3.7, while the current market price is just $1.1. This means that the stock is currently trading at a 70.6% discount to its intrinsic value, making it an attractive investment opportunity for long-term investors. More…
Peers
The pharmaceutical industry is fiercely competitive, with companies constantly vying for market share. This is especially true in the case of Lexicon Pharmaceuticals Inc, which faces stiff competition from Calithera Biosciences Inc, Shanghai Allist Pharmaceuticals Co Ltd, and Incyte Corp.
– Calithera Biosciences Inc ($NASDAQ:CALA)
Calithera Biosciences Inc is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of small molecule drugs for the treatment of cancer. The company’s market cap as of 2022 is 12.7M. The company’s ROE for the same year is -212.85%. The company’s focus on the development and commercialization of small molecule drugs for the treatment of cancer makes it a unique player in the biopharmaceutical industry.
– Shanghai Allist Pharmaceuticals Co Ltd ($SHSE:688578)
Shanghai Allist Pharmaceuticals Co Ltd is a pharmaceutical company with a market cap of 10.34B as of 2022. The company’s return on equity is -1.27%. Shanghai Allist Pharmaceuticals Co Ltd is engaged in the research and development, manufacture and sale of pharmaceutical products.
– Incyte Corp ($NASDAQ:INCY)
Incyte Corporation is a biopharmaceutical company that discovers, develops, and commercializes small molecule drugs to treat serious unmet medical needs, primarily in oncology. As of 2022, Incyte has a market capitalization of $17.25 billion and a return on equity of 9.94%. The company’s primary focus is on the development of drugs for the treatment of cancer. Incyte’s most popular drug, Jakafi (ruxolitinib), is approved for the treatment of several types of blood cancers. Incyte is also investigating other potential uses for Jakafi, including the treatment of solid tumors.
Summary
Lexicon Pharmaceuticals reported third quarter FY2023 earnings on November 8, 2023, with total revenue of USD 0.2 million and net income of USD -50.5 million. This represented a significant decrease from the previous year, with revenue down from USD 0.0 million and a larger decrease in net income from -23.4 million. The stock price reacted negatively to the news, suggesting that investors are not confident in the company’s performance.
When considering an investment in Lexicon Pharmaceuticals, investors should closely analyze the company’s financials and compare them to other similar companies. Furthermore, they should be aware of any pending litigation or other potential issues that could further affect the company’s performance and stock price.
Related Posts
Recent Posts
